Back
Reach Neuro wins FDA Breakthrough approval for device that restores hand & arm movement post-stroke
Back
Lauren McCranie
April 10, 2023
In the US, an estimated 800,000 people per year have a stroke, and nearly half will experience some form of long-term paralysis as a result of permanent damage to the brain’s ability to send signals to muscles. Reach Neuro (IBSF 13) directly restores a patient’s ability to control movement post-stroke, not only giving immediate relief, but also making it possible to return to therapy and continue making even further improvements.
The patients are on board, and now the FDA is too: today, Reach announced that it has been granted an FDA Breakthrough Device designation for its Avantis platform. Avantis uses small electrical impulses delivered to the spinal cord to help restore shoulder, arm, and hand movement to individuals with impairment due to chronic stroke. The FDA designation recognizes the importance of bringing this technology to clinics quickly to address an enormous un-met need for the nearly 7.5 million Americans living with post-stroke disability.
Reach Neuro was founded in 2021 as a spinout company of theUniversity of PittsburghandCarnegie Mellon University, where the technology is currently being tested in an NIH funded clinical trial in collaboration with theUniversity of PittsburghMedical Center (UPMC). The team recently published a manuscript in the journal Nature Medicine, describing the results from the first two study participants. In the study, subjects showed 40% and 108% improvements in grip strength respectively, and up to 124% improvement in joint strength. These improvements enabled them to perform reaching movements more quickly and smoothly than without stimulation (30-40% faster). Participants were also able to perform functional tasks like lifting objects, eating with a fork, and opening a lock. Surprisingly, the researchers observed that some improvements were retained up to one month after the study, even without stimulation. However, patients will likely benefit from having the implant chronically.
“We are excited about the FDA’s recognition of our technology’s potential to change the lives of millions of people living with disability,” saidMarc Powell, Ph.D. CEO, Co-Founder of Reach Neuro. “The Breakthrough Device designation is an incredible opportunity to work closely with FDA experts to expedite the clinical translation of the Avantis system.”
Heather Rendulic, the first participant in the university-lead clinical study describes her experience with the device: “Having the stimulation working and being able to move my arm/hand again after 9 years was one of the most surreal experiences of my life—it was as if my brain was in control of my arm again. This technology gave me such immense hope that one day I will regain a sense of independence again. This will change the lives of millions of people!”
Did you know?
NotCo’s plant-based foods are on store shelves, but its AI engine “Giuseppe” is the real business
While it might look like a plant-based food company, NotCo is in the data and AI business—and aims to disrupt R&D in many industries that use animal and plant ingredients.
Smartex is Creating the Textile Factory of the Future
Gilberto Loureiro grew up inspecting fabrics in a Portuguese textile factory. With Smartex, he and co-founders Antonio Rocha and Paulo Ribeiro are eliminating textile defects—and their enormous cost both to manufacturers and the environment.
Novoloop Is Upcycling Your Future
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
Upside Foods Serves Up a Sustainable Future
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
Sleeping Beauty
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
The Loneliness of the Long-Distance Entrepreneur
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
Chiu Chau Reboots a Robot into a Billion Dollar Business
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
RxAll’s Life-Saving Deep Tech for African Pharmacies
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.
